These studies indicate that the differentiation pathway of tumor‐specific CD8+TRM cells diverges from those of CD8+TRM cells generated during infections, raising important questions about the mechanisms of CD8+TRM cell persistence and functionality in tumors, which may impact therapeutic strategies aimed at enhancing antitumor immunity (Figure 2A). The gene discussed is CD8A; the disease is neoplasm.